Bessemer Group’s Virtus Biotech ETF BBP Stock Holding History

Bessemer Group’s Portfolio BBP Stock Details BBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27	Closed	-$2K	–	2526
2026 Q1	$2K	Buy	+27	New	+$2.22K	﹤0.01%	2349

Other funds holding BBP

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

WBI Investments Red Bank, New Jersey $403M AUM 42.23% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bessemer Group's BBP Position: Q2 2026 in Review

Bessemer Group sold out of Virtus Biotech ETF (BBP) in Q2 2026, closing a stake of 27 shares — an estimated $2K sold.

Bessemer Group first reported a position in BBP in Q1 2026 and held it in 1 quarter. The position peaked at $2K in Q1 2026. 25 funds tracked by Wall St. Rank hold BBP as of Q2 2026.

Bessemer Group reported no remaining Virtus Biotech ETF position as of Q2 2026 after selling out during the quarter.
Bessemer Group sold 27 Virtus Biotech ETF shares in Q2 2026, an estimated $2K.
Bessemer Group first reported a position in Virtus Biotech ETF in Q1 2026 and held it in 1 quarter.
Bessemer Group's Virtus Biotech ETF position peaked at $2K in Q1 2026.
25 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.